In the news
See all news
November 23, 2017
GCT was recently rated based on the business credit information by the world’s most credible and comprehensive source of commercial data.
November 13, 2017
We are proud to announce that GCT was selected as the contractor by the Polish Pharma company in connection with their participation in the Operational Program Intelligent Development 2014-2020, which is organized by the National Center for Research and Development in Poland.
During the tender, GCT has gained the highest score based on the strict selection criteria. It is always a goal for us to meet the requirements of our Sponsors and we look forward to start yet another successful collaboration.
A randomized multicenter controlled Phase IIa clinical trial on a novel pharmaceutical topical gel for wound healing will be performed by GCT in several European countries with participation of 15 clinical sites.
October 26, 2017
We are delighted to announce that both EC and RA approvals to conduct clinical trial in Benign Prostatic Hyperplasia patients were received by GCT team earlier this week. We are preparing for the site initiation in order to start screening and enrollment procedures in November.
Benign Prostatic Hyperplasia is the non-cancerous enlargement of the prostate, affecting about 50% of men above 60 years of age and more than 70% of men ages 70 and above. Please contact us at firstname.lastname@example.org to navigate through the clinical, regulatory and logistical aspects of conducting device and pharmaceutical trials in Slovakia and other EU countries.